(Supplementary Fig. 1): DTCM-glutarimide suppressed luminal occlusion in a dose-dependent fashion.
(Supplementary Fig. 2):
Serum starved VSMCs were added various concentration of DTCM-glutarimide with 0.2% or 10 % FCS for 6 hours. Cell viability was determined using a cell counting kit.
Serum starved VSMCs were added various concentration of IFN-γ (0.01 – 10 ng/ml) for 24 hours. IFN-γ stimulation alone was insufficient to promote proliferation of VSMCs.
(Supplementary Fig. 4):
Quiescent VSMCs were stimulated with b-FGF (20 ng/ml) and incubated with 0.2% DMSO. ERK, p38MAPK and JNK were measured at 0, 15, 30 and 60 minutes after b-FGF stimulation.
Supplementary Figure S5

(A): Blots are representative of 3 independent experiments examining mTOR pathways. 2 hours after b-FGF stimulation, immunoblots were analyzed by densitometry; the results are shown compared to control.

(Supplementary Fig. 5AB): VSMCs were stimulated with b-FGF (20 ng/ml) and incubated with various condition of DTMC-glutarimide. (A) Blots are representative of 3 independent experiments examining mTOR pathways. 2 hours after b-FGF stimulation, immunoblots were analyzed by densitometry; the results are shown compared to control.